Alliances
The 3-year project aims to lower the cost of manufacturing mAbs significantly - to $5/g.
The company has been especially active in diabetes management with collaboration partners that include medical device giant Medtronic and DexCom.
The company secured a deal to equip Rigshospitalet and Herlev Hospital with modern treatment systems over the next few years.
Novartis announced they have expanded their collaboration with the Banner Alzheimer’s Institute to launch a new clinical trial in ALZ’s.
Dicerna and Boehringer Ingelheim today announced a research collaboration and license agreement to discover and develop novel RNAi therapeutics for the treatment of chronic liver diseases.
CryoPort handles the products for more than 172 of the more than 800 immunotherapy trials underway.
The companies will advance the new Relaxin development candidate, AZD7970, toward the clinic as an investigational treatment for heart failure.
Maxhealth Medicine of Wuxi, China struck a deal with Switzerland’s Legacy Healthcare to commercialize Legacy’s CG 210 in Mainland China and Macao.
Shares of Voyager have fallen more than 12 percent in premarket trading after Sanofi Genzyme walked away from its $845M gene therapy treatment for Parkinson’s disease.
Astra and Incyte are pushing forward on the development of immunotherapy combination treatments.
PRESS RELEASES